(b)(4).Title: surgical pulmonary valve replacement: a benchmark for outcomes comparisons citation: j thorac cardiovasc surg 2014;148:1450-3 authors: e.Dean mckenzie, md, muhammad s.Khan, md, thomas w.Dietzman, bs, et al.No unique device identifier (serial/lot) numbers were provided; without this information it cannot be determined whether this event has been previously reported.(b)(4).
|
Medtronic received information via literature review that a retrospective study (july 1995 to december 2010) was performed to evaluate outcomes of pulmonary valve/conduit replacement (pvr) at a large pediatric hospital to provide contemporary benchmark data for comparison with developing technologies.The study population included 148 patients (predominantly male, median age of 15.9 years, median weight 55.3 gk), 52 of which were implanted with a medtronic bioprosthesis (three product families, serial numbers not provided).Multiple patients and multiple manufacturers were noted in the article, however, a one-to-one correlation could not be made between events and product.Among all patients two deaths occurred on follow-up after 2 years post-implant (causes of death were secondary to severe cardiac dysfunction and a respiratory tract infection leading to respiratory failure); neither death was attributed to medtronic product.One noted adverse event included an intervention secondary to mediastinal hematoma in which no active bleeding was identified.Additionally, other interventions occurred, noted as freedom from pulmonary valve re-intervention at 1, 3, and 5 years was 99%, 99%, and 94% respectively, however no other details were provided.No additional adverse patient effects were reported.
|